McKinley N, McCain S, Kirk S
South Eastern Health and Social Care Trust.
Ulster Med J. 2017 Sep;86(3):177-180. Epub 2017 Sep 12.
Male breast cancer accounts for less than 1% of breast cancers with published overall and disease free survival being lower than in females.
To determine treatment and long term outcomes for male breast cancer patients in our unit.
A database has been maintained for all breast cancer patients diagnosed in our unit since 1993. Patients were identified using the database and information was collated on patient demographics, tumour pathology, treatment and outcomes using the database and retrospective chart review. Patients were followed to cause of death.
From 1994-2009 twenty-four cancers were diagnosed in twenty-two patients. Mean age at diagnosis was 69. Male breast cancer patients were treated using similar principles to female breast cancer. Twenty patients underwent mastectomy, two patients underwent wide local excision. No patients developed local recurrence. One patient died from their breast cancer with systemic metastases. 10-year overall survival was 22%, 10 year disease-specific survival was 80%. Other causes of death included medical co-morbidity and secondary cancers.
Disease free survival in our unit is comparable to other published studies. High age at diagnosis and co-morbidity are the most important factors in determining overall outcome. Treatment pathways for male breast cancer should follow guidelines for female disease in order to optimise outcomes. Future research at national or international level is necessary to ensure the most effective treatments are implemented for male breast cancer patients.
男性乳腺癌占乳腺癌总数的比例不到1%,已发表的总体生存率和无病生存率低于女性。
确定我院男性乳腺癌患者的治疗方法和长期预后。
自1993年以来,我院对所有确诊的乳腺癌患者建立了数据库。通过数据库识别患者,并利用数据库和回顾性病历审查收集患者人口统计学、肿瘤病理学、治疗方法和预后等信息。对患者进行随访直至死亡原因明确。
1994年至2009年期间,22名患者被诊断出患有24例癌症。确诊时的平均年龄为69岁。男性乳腺癌患者的治疗原则与女性乳腺癌相似。20例患者接受了乳房切除术,2例患者接受了局部广泛切除术。没有患者出现局部复发。1例患者因乳腺癌伴全身转移死亡。10年总生存率为22%,10年疾病特异性生存率为80%。其他死亡原因包括合并症和继发性癌症。
我院的无病生存率与其他已发表的研究相当。确诊时年龄较大和合并症是决定总体预后的最重要因素。男性乳腺癌的治疗途径应遵循女性疾病的指南,以优化治疗结果。有必要在国家或国际层面开展未来研究,以确保为男性乳腺癌患者实施最有效的治疗方法。